While tumor size and metastatic spread are of the utmost importance for prognosis, so are tumor grade, proliferation and expression of estrogen- (ER), progesterone- (PgR) and HER2-receptors, and these clinicopathological features guide therapy decision-making [2, 3]. The gene discussed is ERBB2; the disease is neoplasm.